A group of eminent allergy and respiratory professors presented data specifically addressing numerous key questions within the allergy community concerning grass sublingual immunotherapy (SLIT) tablets, with specific focus on GRAZAX, for the treatment of grass pollen allergy.
Data presented to physicians at the European Academy of Allergy and Clinical Immunology (EAACI) congress showed that the ALK grass SLIT-tablet, GRAZAX, is an efficacious treatment option for patients with clinically relevant symptoms to any of the temperate grasses. Indirect comparisons also demonstrated grass SLIT-tablets and grass SCIT (sub-cutaneous immunotherapy) are equally efficacious.
Furthermore, grass SLIT-tablets have the benefit of being less invasive than SCIT, and convenient for patients to take in their own home rather than having to visit the hospital or doctor’s office.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive